SCHEMBL2068167

SCHEMBL2068167

CC(=O)OCc1ncc(B2OC(C)(C)C(C)(C)O2)cc1NCC(=O)OC(C)(C)C

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 1/20 0.39
PRMT5 O14744 1/20 0.37
WDR77 Q9BQA1 1/20 0.37
GSK3A P49840 1/20 0.37
GSK3B P49841 1/20 0.37
USP30 Q70CQ3 2/20 0.36
AAK1 Q2M2I8 3/20 0.36
HIF1A Q16665 3/20 0.35
PDGFRB P09619 2/20 0.32
KDR P35968 2/20 0.32
FFAR1 O14842 1/20 0.31
BACE1 P56817 1/20 0.30
BACE2 Q9Y5Z0 1/20 0.30
ALPL P05186 1/20 0.30
THRB P10828 1/20 0.30
TDP1 Q9NUW8 1/20 0.30
CCNT1 O60563 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2068063 0.90 GSK3A (0.39) DGAT1PRMT5WDR77GSK3AGSK3B
SCHEMBL2068168 0.77 USP30 (0.40) DGAT1PRMT5WDR77GSK3AGSK3B
SCHEMBL2068061 0.76 USP30 (0.39) DGAT1PRMT5WDR77GSK3AGSK3B
SCHEMBL2066143 0.75 GSK3A (0.41) DGAT1PRMT5WDR77GSK3AGSK3B
SCHEMBL2068556 0.74 DGAT1 (0.41) DGAT1PRMT5WDR77GSK3AGSK3B
SCHEMBL2068172 0.70 GSK3A (0.41) DGAT1PRMT5WDR77GSK3AGSK3B
SCHEMBL2067654 0.70 DGAT1 (0.37) DGAT1GSK3AGSK3BUSP30AAK1
SCHEMBL16283827 0.70 AAK1 (0.48) DGAT1PRMT5WDR77USP30AAK1
SCHEMBL21159762 0.70 PRMT5 (0.40) DGAT1PRMT5WDR77GSK3AGSK3B
SCHEMBL2067799 0.69 AAK1 (0.34) AAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2438063-A1 1H-IMIDAZO[4,5-C]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES Novartis AG (CH) 2012-04-11 EP disclosed
WO-2010139747-A1 1H-IMIDAZO[4, 5-c]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES NOVARTIS AG (CH) 2010-12-09 WO disclosed
US-20100311714-A1 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS NOVARTIS AG (CH) 2010-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100311714-A1 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS PRKCA, ABL1, MYLK2 DGAT1 941/4885PRMT5 385/4885WDR77 2163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.